Browsing Tag
ENFLONSIA
2 posts
Merck (NYSE: MRK) reports Q2 loss, hikes revenue view as Keytruda Qlex ramps
Merck raised 2026 sales guidance to $67.3B but cut EPS to $2.76 on Terns charge. Lipfendra approval and $463M Keytruda Qlex quarter reshape the 2028 cliff.
Merck (NASDAQ: MRK) wins FDA approval for ENFLONSIA to prevent RSV in infants
FDA clears Merck’s ENFLONSIA (NASDAQ: MRK) for RSV prevention in infants. See trial data, stock reaction, pediatric market impact & analyst projections.